The India Pharmaceutical Industry is developing, producing and marketing drugs.
The pharmaceutical companies are generally dealing in generic or brand medications and medical device.
Indian Pharmaceutical Industry today is in the front rank of India’s science-based industries with wide ranging capabilities in the complex field of drug manufacture and technology.
India enjoys a important position in the global pharmaceutical market. The Indian pharmaceuticals market is the third largest in terms of volume and thirteenth largest in terms of value.
It ranks very high in the third world, in terms of technology, quality and range of medicines manufactured.
complete description about pharmaceutical industry how it work how it is operated both at micro as well as macro level. it also include leading pharma firms in market. in simple words if we say it is an industry analysis.
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
PRESENT SCENARIO OF INDIAN PHARMACEUTICAL INDUSTRY IN VIEW OF GLOBAL ...sridivyaannavarapu
THE INDIAN GOVERNMENT HAS STARTED TO ENCOURAGE THE GROWTH OF DRUG MANUFACTURING BY INDIAN COMPANIES IN THE EARLY 1960s. AT PRESENT THERE ARE MANY NUMBER OF PHARMACEUTICAL COMPANIES IN INDIA WITH MANY NOVEL DRUG INVENTORIES
Trends & Opportunities for Indian Pharma is a knowledge paper highlighting the upcoming trends and related opportunities in Indian pharmaceuticals industry
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.Audumbar Mali
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
B. Pharm. Final Year, Sem-VIII, BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory),
As PCI Syllabus.
This presentation is about the basic responsibilities and functions of CDSCO explaining the regulatory body's constitution, comprising of functions of state licensing authority and port offices covering the guidelines for new drug approval process, clinical trails and medical devices. this presentation also give a basic note on SUGAM
Abbreviated New Drug Application [ANDA]Sagar Savale
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.Audumbar Mali
Unit-III, Chapter 1. Registration of Indian Products in Overseas Market.
B. Pharm. Final Year, Sem-VIII, BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory),
As PCI Syllabus.
This presentation is about the basic responsibilities and functions of CDSCO explaining the regulatory body's constitution, comprising of functions of state licensing authority and port offices covering the guidelines for new drug approval process, clinical trails and medical devices. this presentation also give a basic note on SUGAM
Abbreviated New Drug Application [ANDA]Sagar Savale
An Abbreviated New Drug Application (ANDA) contains data which when submitted to FDA's CDER, Office of Generic Drugs, provides for the review and ultimate approval of a generic drug product.
its a research on patanjali to know out the influencing factors of customer to buy patanjali product as well to to study the effect of factors on customer satisfaction. it is both primary as well as secondary study. it is a very neede study on 100 responses as well as some of the personal interviews. italso include patanjali ayurveda entry nto fmcg market and restraurant market..
its a ppt about hoe mcd adopted various techniques to survive in india.. what were the different challenges faced by mcd in india....
and what are the marketting strategies of mcd...
demonetization : impact on hawkers and vendorsTrishala Gautam
his is a presentation on impact of demonetization on hawkers and vendors. basically it is based on demonetization done on 8th nov 2016 by Indian PM Narndra madi...
it tells what was the impact of demonetization on hawkers and vendors and whether they were able to cover up or not at that time.
its a primary study
and sample size is low coz of limited time slot...
this is a kind of research paper on financial inclusion and e-banking services awareness among the customer of State Bank of India with special reference to customer of Agra...
the sample size of study is small because of limited time periiod...
this is a presentation which tells about the current status of financial inclusion in India as well as awareness regarding the use of ATM among the customer of State Bank of India. its a primary study based on random sampling and questionnaire format... hope you may like it
Strategic partnership between european union & indiaTrishala Gautam
its a presentation on strategic partnership between european union and india. It includes different sub topics such as Chronological events, EU-India strategic partnership, EU-India Summit 2016, trade in goods and investment, 30 years of development and various other topics also...
its a presentation in hindi on topic textile idustry in india it gives introduction to textile industry tells its history,gives organization structure of industry, swot analysis, factors affecting textile industry production, indias rank in textile industry, recent development , export scenario, india cloth export 2016
its a presentation on census 2011 it shows various data which is very much helpful in knowing various data such as population rate, literacy rate, sex ratio etc....
it would be very much helpful in planning different policies...
it also tells about the history of census and as well as its importance
ita a scheme statrted in 2009 by congress. earlier it waas known as jawahar lal nehru national solar mission bt recently its name change into national solar mission
Deep Leg Vein Thrombosis (DVT): Meaning, Causes, Symptoms, Treatment, and Mor...The Lifesciences Magazine
Deep Leg Vein Thrombosis occurs when a blood clot forms in one or more of the deep veins in the legs. These clots can impede blood flow, leading to severe complications.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Empowering ACOs: Leveraging Quality Management Tools for MIPS and BeyondHealth Catalyst
Join us as we delve into the crucial realm of quality reporting for MSSP (Medicare Shared Savings Program) Accountable Care Organizations (ACOs).
In this session, we will explore how a robust quality management solution can empower your organization to meet regulatory requirements and improve processes for MIPS reporting and internal quality programs. Learn how our MeasureAble application enables compliance and fosters continuous improvement.
Explore our infographic on 'Essential Metrics for Palliative Care Management' which highlights key performance indicators crucial for enhancing the quality and efficiency of palliative care services.
This visual guide breaks down important metrics across four categories: Patient-Centered Metrics, Care Efficiency Metrics, Quality of Life Metrics, and Staff Metrics. Each section is designed to help healthcare professionals monitor and improve care delivery for patients facing serious illnesses. Understand how to implement these metrics in your palliative care practices for better outcomes and higher satisfaction levels.
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
2. CONTENTS
• Introduction
• Snapshot
• Evolution
• Structure
• Industrial analysis technique-PESTEL & SWOT (Rhea & Rohit)
• Micro analysis of the industry –interview method (Krishna, Shubham & Jayashree)
• Comparison between micro and macro (Jayashree)
• Company profile
1. Sun pharma
2. Lupin
3. Dr Reddy
Gaurav Aitwani
Trishala Gautam
3. INTRODUCTION
• The India Pharmaceutical Industry is developing, producing and marketing
drugs.
• The pharmaceutical companies are generally dealing in generic or brand
medications and medical device.
• Indian Pharmaceutical Industry today is in the front rank of India’s science-based
industries with wide ranging capabilities in the complex field of drug manufacture
and technology.
• India enjoys a important position in the global pharmaceutical market. The
Indian pharmaceuticals market is the third largest in terms of volume and
thirteenth largest in terms of value.
• It ranks very high in the third world, in terms of technology, quality and range of
medicines manufactured.
4. SNAP SHOT
S.no. Metric Value
1 Turnover USD36.7 billion
2 Employees 29 MILLION
3 % of GDP 2%
4 FX earning USD 16.8 billion
5 Tax (contribution) 25%
6 Imports 254.57 USD Million
7 Exports US$ 16.4 billion
5. BEFORE THE
PASSING OF THE
INDIAN PATENT ACT
OF 1970 the indian
pharmaceutical
industry was
dominated by foregin
companies with little
domestic
participation
The INDIAN PATENT
ACT was passed in
1970 and led to the
development of
production
infrastructure.The
period beween1970-
1990 led to the
operation of several
domestic companies
during this period as
well as export
initiatives were also
taken during this
period.
THE 3rdSTAGE(1990-
2010)-During this
period the
liberalization led
Indian components
to launch operations
in foreign
countries. The
Patents Act was
amended in the year
2005 which led to
adoption to product
patents in
India. During this
period India became
a major generic drug
manufacturing
country
In 2013 New Drug
Pricing Control
Order were issued
by Directorate of
Food and Drugs
that were expected
reduce the prices
of drugs by 80%.
Further in
2014,100% FDI was
allowed in medical
device industry.
. In 2015, the
patent was
amended which
included the
amendments done
in the PATENT ACT
2002.
EVOLUTION
9. POLITICAL
• Governments
• Developing
countries
ECONOMIC
• The reduction in consumer
disposable income.
• These economic pressures
leading to increase startergic
buying
• Increased pressure from
shareholders
SOCIAL
It includes cultural change,
health problem, population
growth rate etc.
TECHNOLOGICAL
1. New info and Communications
technologies.
2. Social Media for Healthcare.
3. Customized Treatments.
4. Direct to Patient Advertising.
5. Direct to patient communications.
10. LEGISLATION Factors include consumer law,
employment law, and health and safety
law.
ENVIRONMENTAL
• Business and marketing plans link in
with the environmental issues.
• Corporate Social Responsibility
programmes.
• Eco opportunities
11. STRENGTH
• Competitive Production cost and drug
quality
• Speedy Clinical Trials
• Strong Focus by the Government
WEAKNESS
• Volatile Foreign
Exchange
• Low R&D investment
• Import dependence for
Bulk drugs
12. Opportunities
• Patent Cliff
• Optimistic targets by Government
• New markets- Rural Penetration
• Increasing global demand for
generics
Threat
• High Dependence on US market
• Growing threats from China API’s market
• IP regulations by developed countries are
getting tougher
15. PESTEL ANALYSIS
•Effect of GST
•Maintenance of stock
•Preference in regard to generic or branded
medicines
•Profit margin in regard to different customers
•Seasonal Variations
17. STRENGTH
• Licensing and authorization
• Variety of products
• Inelastic demand
• Approach to all sections of society
WEAKNESS
• High level of
competition
• Shelf life of stock is low
• Regulatory changes
• Unskilled manpower
18. Opportunities
• Wider market coverage , eg : selling
of both generic and non generic
drugs
• Tie up with upcoming pharma brands
Threat
•Competition from ancillary markets
•Threat of substitutes
•Threat of new entrants
19. COMPARISION
DESCRIPTION MICRO MACRO
ENTRY BARRIERS LOW HIGH
SUBSTITUTES HIGH LOW
COMPETITORS HIGH HIGH
SEASONAL VARIATIONS LOW HIGH
DEMAND CHAIN COMPLEX SIMPLE
POLITICAL DIRECT EFFECT INDIRECT EFFECT
20. COMPARISION
DESCRIPTION MICRO MACRO
ECONOMICAL EXPECTED TO GROW IN
FUTURE
STEADY GROWTH
SOCIAL LOW CORPORTAE SOCIAL
RESPONSIBILITY
HIGH CORPORATE SOCIAL
RESPONSIBILITY
TECHNOLOGICAL WIDE USAGE LESS USAGE
STRENGTHS COMPETITIVE PRODUCTION
COST, DRUG QUALITY
INELASTIC DEMAND, VARIETY
OF PRODUCTS
WEAKNESS LOW R & D INVESTMENT HIGH COMPETITION, LESS
SHELF LIFE
OPPORTUNITY INCREASING GLOBAL DEMAND WIDER MARKET COVERAGE
THREATS CHANGES IN REGULATORY
ENVIRONMENT
COMPETITION FROM
ANCILLARY MARKETS, THREAT
OF SUBSTITUTES
21. Dr Reddy Lupin SunPharma
Aurbindo Cipla
TOP 5 LEADING COMPANIES
POLITICAL
Governments often have great purchasing power and affect the industry most in political way and control the prices of the product in the industry.
' have dominate on manufacturing and increasing R&D investment. Those organizations tend to sell their product to high demand developing countries in higher prices
ECONOMIC
1. The reduction in consumer disposable income will have an impact on those countries using health insurance models particularly where part payment is required.
2. These economic pressures are seeing an increased growth in strategic buying groups who are forcing down prices.
3. Increased pressure from shareholders has caused a consolidation of the industry: more mergers and acquisitions will take place over the coming years.
SOCIAL
1. It includes cultural change, health problem, population growth rate etc. Social factors affect the demand of a company's products and how it operates. According to the case, ageing population and Medicare is reformed, extended drug coverage for elderly.
2. As population is becoming older, it means the demand of medicine also increases. Nowadays, population raise, also require more medicine.
TECHNOLOGICAL
Technological advancements will create new business prospects both in terms of new therapy systems and service provisions. The online opportunities will see the growth in:
New info and Communications technologies.
Social Media for Healthcare.
Customized Treatments.
Direct to Patient Advertising.
Direct to patient communications
LEGISLATION
Factors include consumer law, employment law, and health and safety law.
Pharmaceutical industry is subjected to regulatory and the department will examine all the data to support the safety, efficacy and stability.
Pharmaceutical promotion is subjected to self-regulation. Representative requires passing all the examination testing of medical knowledge. Some countries, government require the agency to check if the promotional claim is consistency with the data.
ENVIRONMENTAL
There is a growing environmental agenda and the key stake holders are now becoming more aware of the need for businesses to be more proactive in this field. Pharma companies need to see how their business and marketing plans link in with the environmental issues. There is also an opportunity to incorporate it within their Corporate Social Responsibility programmes. Marketing and new product development should identify eco opportunities to promote as well.
WEAKNESS
1) The Indian pharmaceuticals industry is export oriented, and it contributes to over 50% of pharma revenues. Hence, any fluctuation in currency leads to instability in receivables. In the last one year, Indian currency has depreciated by over 20% in a year against major currencies which has led to renegotiation by the importers.
2) Global pharma industry is highly driven by the amount of R&D made by the firms and companies spend over 15% of their annual revenue on R&D. However, Indian pharma companies invest just 4% of the revenue for R&D.
3) Although India represents over 30% of global generic drug consumption, over 80% of the required APIs are imported from China.
OPPORTUNITIES
As pointed out by a credit rating company, drug patent expiry in the USA will create new opportunity for Indian pharmaceutical industry in the coming years. ‘Patent Cliff’, a term used to describe the phenomenon of drugs approaching theirpatent expiration date, resulting in steep decline in sales of the branded drug as cheaper generics enter the market place to replace the branded drugs. Indian pharmaceutical companies have the opportunity to capitalize on the patent cliff and gain a greater share of the growing generics market.
The Indian pharmaceutical sector is targeting a 5% share of the global pharmaceutical market by the end of the Twelfth Five Year Plan. India currently has 2.4% market share globally. Some of the key expectations outlined in the Plan are:
Exports should be at USD 20 billion by the end of the Twelfth Five Year Plan (year 2017)
The sector should employ 1.5 million people by 2015, 1.898 million people by 2018 and 2.464 million people by 2022.
Domestic R&D should be internationally competitive
Improve domestic content in medical devices.
THREATS
The bulk drug industry in china is expanding rapidly and Indian exporters are finding it difficult to get a foothold in the Chinese market. Chinese APIs are approximately 1520 per cent cheaper compared to Indian APIs, and over 50 per cent of bulk drugs used in the industry for making formulations are imported from China
The U.S. is the top destination for Indian pharma exports followed by the UK. India’s pharmaceutical exports registered a sluggish growth offlate because of the growing tension with the US authorities over intellectual property rights related issues. Key developed nation export destinations like US, EU region has increased scrutiny and import alerts on Indian facilities and products over the recent past. This has adversely affected exports of several large medicine manufacturers.